{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0090303",
      "entity_text" : "injury",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02731",
      "entity_text" : "eculizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Thus, eculizumab, at therapeutic levels, can reduce ongoing endothelial damage and renal injury from terminal complement in spite of ongoing chronic alternative complement pathway activation.",
  "reading_complete" : "2020-08-03T15:27:10Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T15:26:37Z",
  "trigger" : "reduce",
  "evidence" : [ "eculizumab, at therapeutic levels, can reduce ongoing endothelial damage and renal injury" ],
  "pmc_id" : "4974426",
  "score" : 0
}